Inovio Pharma (INO), Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Inovio Pharma (INO), Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO's COVID-19 DNA Vaccine Candidate

Inovio Pharma (INO) Misses Q2 EPS by 14c

August 9, 2021 4:51 PM EDT

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

... More